Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 23, Pages 5993
Publisher
MDPI AG
Online
2021-11-29
DOI
10.3390/cancers13235993
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma
- (2021) MITSUTAKE YANO et al. ANTICANCER RESEARCH
- The Risks of miRNA Therapeutics: In a Drug Target Perspective
- (2021) Song Zhang et al. Drug Design Development and Therapy
- Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer
- (2021) Vijayalaxmi G. Gupta et al. GYNECOLOGIC ONCOLOGY
- The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance
- (2021) Takeshi Motohara et al. SEMINARS IN CANCER BIOLOGY
- Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality
- (2021) Joonas Jukonen et al. Scientific Reports
- DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application
- (2021) Chunhong Hu et al. Clinical Epigenetics
- Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers
- (2021) David W. Chan et al. Clinical Epigenetics
- Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer
- (2021) Li-yuan Feng et al. Clinical Epigenetics
- Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients
- (2021) Xiao-fei Li et al. Frontiers in Oncology
- A short guide to histone deacetylases including recent progress on class II enzymes
- (2020) Suk-Youl Park et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
- (2020) Sara Moufarrij et al. Scientific Reports
- Targeting DNA Repair in Ovarian Cancer Treatment Resistance
- (2020) M.W. Wong-Brown et al. CLINICAL ONCOLOGY
- miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling
- (2020) Matthew Knarr et al. Nature Communications
- Identification of Chemoresistance-Associated Key Genes and Pathways in High-Grade Serous Ovarian Cancer by Bioinformatics Analyses
- (2020) Yong Wu et al. Cancer Management and Research
- Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?
- (2020) Ali A. Alshamrani Frontiers in Oncology
- Methylomic Signatures of High Grade Serous Ovarian Cancer
- (2020) Horacio Cardenas et al. Epigenetics
- HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells
- (2020) Ahlam Ali et al. Cancers
- ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer
- (2019) Shoko Mase et al. CANCER SCIENCE
- A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
- (2019) Marie Sébert et al. HAEMATOLOGICA
- Epigenetic activation of POTE genes in ovarian cancer
- (2019) Ashok Sharma et al. Epigenetics
- Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines
- (2019) Jan J. Bandolik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
- (2019) Guillermo Garcia-Manero et al. Lancet Haematology
- Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis
- (2019) Yaowei Li et al. Journal of Ovarian Research
- A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
- (2019) Amit M. Oza et al. CLINICAL CANCER RESEARCH
- A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses
- (2018) Daniela Matei et al. CLINICAL CANCER RESEARCH
- Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment
- (2018) Belinda van Zyl et al. ENDOCRINE-RELATED CANCER
- Epigenetics and MicroRNAs in Cancer
- (2018) Alice Ramassone et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Association of histone deacetylase expression with histology and prognosis of ovarian cancer
- (2018) Mitsutake Yano et al. Oncology Letters
- The Epithelial-to-Mesenchymal Transition in Cancer
- (2018) Joëlle Roche Cancers
- Gap Junction Intercellular Communication Positively Regulates Cisplatin Toxicity by Inducing DNA Damage through Bystander Signaling
- (2018) Sanjeevani Arora et al. Cancers
- Histone Deacetylase Inhibitors as Anticancer Drugs
- (2017) Tomas Eckschlager et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
- (2017) Meredith L. Stone et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ovarian cancer stem cells more questions than answers
- (2017) Petronella Beatrix Ottevanger SEMINARS IN CANCER BIOLOGY
- DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer
- (2017) Riikka J. Lund et al. Scientific Reports
- Combining Epigenetic and Immunotherapy to Combat Cancer
- (2016) Katherine B. Chiappinelli et al. CANCER RESEARCH
- Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer
- (2016) N. A. Bonito et al. CLINICAL CANCER RESEARCH
- Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib
- (2016) Andrew J. Wilson et al. GYNECOLOGIC ONCOLOGY
- Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer
- (2016) A E Witt et al. ONCOGENE
- Histone Modifications and Cancer
- (2016) James E. Audia et al. Cold Spring Harbor Perspectives in Biology
- Epigenetic Determinants of Cancer
- (2016) Stephen B. Baylin et al. Cold Spring Harbor Perspectives in Biology
- Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer
- (2016) Shailendra Kumar Dhar Dwivedi et al. Oncotarget
- Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways
- (2016) Tushar Tomar et al. Genome Medicine
- Signal Transduction Pathways of EMT Induced by TGF-β, SHH, and WNT and Their Crosstalks
- (2016) Jingyu Zhang et al. Journal of Clinical Medicine
- Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer
- (2015) Ursula Matulonis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- DNA methylation abnormalities in congenital heart disease
- (2015) Clara Serra-Juhé et al. Epigenetics
- Elevated AKAP12 in Paclitaxel-Resistant Serous Ovarian Cancer Cells Is Prognostic and Predictive of Poor Survival in Patients
- (2015) Nicholas W. Bateman et al. JOURNAL OF PROTEOME RESEARCH
- The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies
- (2015) Ke Yang et al. LABORATORY INVESTIGATION
- Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
- (2015) Jean-Pierre J Issa et al. LANCET ONCOLOGY
- The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells
- (2015) Anamaria Brozovic et al. Molecular Oncology
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- Targeting Notch, Hedgehog and Wnt pathways in cancer stem cells: clinical update
- (2015) Naoko Takebe et al. Nature Reviews Clinical Oncology
- Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma
- (2015) Chia-Ming Yeh et al. Oncotarget
- Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
- (2015) Erika Héninger et al. Frontiers in Immunology
- Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer
- (2015) Li Zhang et al. Oncotarget
- Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas
- (2015) Wilko Weichert et al. NEOPLASIA
- A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
- (2014) R M Glasspool et al. BRITISH JOURNAL OF CANCER
- Anti-miR182 Reduces Ovarian Cancer Burden, Invasion, and Metastasis: An In Vivo Study in Orthotopic Xenografts of Nude Mice
- (2014) X. Xu et al. MOLECULAR CANCER THERAPEUTICS
- DNA methylation profiles in ovarian cancer: Implication in diagnosis and therapy (Review)
- (2014) OURANIA KOUKOURA et al. Molecular Medicine Reports
- The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer
- (2014) Dineo Khabele Frontiers in Oncology
- Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients
- (2013) Ying-Cheng Chiang et al. ENDOCRINE-RELATED CANCER
- Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis
- (2013) Elena Lum et al. GYNECOLOGIC ONCOLOGY
- MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas
- (2013) Yu-Quan Wang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition
- (2013) Chaoyang Sun et al. JNCI-Journal of the National Cancer Institute
- A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis
- (2013) A. Vecchione et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evaluating cell lines as tumour models by comparison of genomic profiles
- (2013) Silvia Domcke et al. Nature Communications
- Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
- (2013) M. Nishimura et al. Cancer Discovery
- Epigenetic alteration and microRNA dysregulation in cancer
- (2013) Hiromu Suzuki et al. Frontiers in Genetics
- Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12
- (2012) Irwin H. Gelman CANCER AND METASTASIS REVIEWS
- Epigenetic Resensitization to Platinum in Ovarian Cancer
- (2012) D. Matei et al. CANCER RESEARCH
- Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer
- (2012) Sergio Marchini et al. EUROPEAN JOURNAL OF CANCER
- Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells
- (2012) Xin Fu et al. FEBS LETTERS
- A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study
- (2012) Don S. Dizon et al. GYNECOLOGIC ONCOLOGY
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines
- (2012) Min-Gyun Kim et al. Journal of Gynecologic Oncology
- Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel
- (2012) D. M. Cittelly et al. MOLECULAR CANCER THERAPEUTICS
- DNA Methylation and Its Basic Function
- (2012) Lisa D Moore et al. NEUROPSYCHOPHARMACOLOGY
- Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors
- (2012) A. Gurney et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance
- (2012) Song Gao et al. TUMOR BIOLOGY
- Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer
- (2011) A. D. Steg et al. CLINICAL CANCER RESEARCH
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
- (2010) Siqing Fu et al. CANCER
- A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer
- (2010) Fang Fang et al. CANCER
- The miR-200 family controls -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients
- (2010) S. Leskela et al. ENDOCRINE-RELATED CANCER
- Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer
- (2009) Meng Li et al. BMC Medical Genomics
- Epigenetics in cancer
- (2009) S. Sharma et al. CARCINOGENESIS
- MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents
- (2009) D. R. Cochrane et al. MOLECULAR CANCER THERAPEUTICS
- Causes and consequences of microRNA dysregulation in cancer
- (2009) Carlo M. Croce NATURE REVIEWS GENETICS
- Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis
- (2008) Yanfang Li et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs
- (2008) Kei-ichi Ozaki et al. CANCER SCIENCE
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
- (2008) Sendurai A. Mani et al. CELL
- MicroRNA Expression Profiles in Serous Ovarian Carcinoma
- (2008) E. J. Nam et al. CLINICAL CANCER RESEARCH
- A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2008) Susan C. Modesitt et al. GYNECOLOGIC ONCOLOGY
- Epigenetics in Cancer
- (2008) Manel Esteller NEW ENGLAND JOURNAL OF MEDICINE
- Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition
- (2008) Anne-Pierre Morel et al. PLoS One
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started